排序方式：
1.Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
Li, JiaXin, Ma, LinR
More...
Li, JiaXin, Ma, LinRui, Wang, Peng, Xu, DongHan, Huang, Jie, Li, LiQi, Leung, Elaine LaiHan, Yan, PeiYu, Li, RunZe, Xie, Ying, Tang, Ling
Less
Frontiers in Pharmacology[1663-9812],
Published 2022,
Volume 13,
收錄情况：
WOS
SCOPUS
WOS核心合集引用: 11
2024影響因子:
4.8
发表年影響因子:
5.6
2.Targeting Notch signaling pathways with natural bioactive compounds: a promising approach against cancer
Yang, J, Sun, QH, Li
More...
Yang, J, Sun, QH, Liu, XY, Yang, Y, Rong, R, Yan, PY, Xie, Y
Less
FRONTIERS IN PHARMACOLOGY[1663-9812],
Published 2024,
Volume 15,
收錄情况：
WOS
SCOPUS
WOS核心合集引用: 4
2024影響因子:
4.8
发表年影響因子:
4.8
3.Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody
Li, JX, Tan, SY, Li,
More...
Li, JX, Tan, SY, Li, LQ, Zheng, YH, Zhao, L, Zhu, HR, He, HL, Zhang, YY, Li, RZ, Bao, TY, Zhang, YZ, Yang, XM, Zhang, H, Chen, HH, Wu, BW, Lin, X, Lin, XS, Lin, YC, Sui, XB, Xie, Y, Zhou, XM, Yan, PY
Less
FRONTIERS IN PHARMACOLOGY[1663-9812],
Published 2025,
Volume 16,
收錄情况：
WOS
SCOPUS
WOS核心合集引用: 0
2024影響因子:
4.8
